Suppr超能文献

牛津脑健康诊所中痴呆风险因素的患病率。

Prevalence of dementia risk factors in the Oxford Brain Health Clinic.

作者信息

Blane J, Gillis G, Griffanti L, Mitchell R, Pretorius P M, Forster S, Shabir S, Maffei L, O'Donoghue M C, Fossey J, Raymont V, Martos L, Mackay C E

机构信息

Oxford Centre for Human Brain Activity, Wellcome Centre for Integrative Neuroimaging, Department of Psychiatry, University of Oxford, Oxford, UK.

Oxford Health NHS Foundation Trust, Oxford, UK.

出版信息

Sci Rep. 2025 Mar 5;15(1):7765. doi: 10.1038/s41598-025-91178-7.

Abstract

With promising disease-modifying therapies (DMTs) emerging and good evidence to support risk reduction in the delay of dementia onset and progression, it is important to understand the profile of patients attending memory assessment services to estimate what proportion of patients might benefit from different types of interventions. The Oxford Brain Health Clinic (OBHC) is a psychiatry-led, clinical-research service that offers memory clinic patients detailed clinical assessments and equal access to research opportunities as part of their secondary care pathway. In this work, we describe the characteristics of OBHC patients in terms of demographics, diagnoses and prevalence of potentially modifiable risk factors compared with a cohort of healthy volunteers and the average memory clinic population. Our results suggest that high research consent rates (91.5%) in the OBHC resulted in a highly representative cohort of the clinical population. Based on Lecanemab trial inclusion criteria, 24.6% of the OBHC population may be suitable for further investigation into DMTs. Furthermore, 67.4% of OBHC patients have at least one potentially modifiable risk factor that may benefit from lifestyle interventions, particularly those focused on depression, sleep and physical activity.

摘要

随着有前景的疾病修饰疗法(DMTs)不断涌现,且有充分证据支持在延缓痴呆症发病和进展方面降低风险,了解接受记忆评估服务的患者情况,以估计有多大比例的患者可能从不同类型的干预措施中获益,这一点很重要。牛津脑健康诊所(OBHC)是一项由精神病学主导的临床研究服务,为记忆门诊患者提供详细的临床评估,并在其二级护理路径中为患者提供平等的研究机会。在这项工作中,我们将OBHC患者的人口统计学特征、诊断情况以及潜在可改变风险因素的患病率,与一组健康志愿者和记忆门诊患者的平均情况进行了比较。我们的结果表明,OBHC的高研究同意率(91.5%)产生了一个具有高度代表性的临床人群队列。根据lecanemab试验纳入标准,24.6%的OBHC人群可能适合进一步研究DMTs。此外,67.4%的OBHC患者至少有一个潜在可改变的风险因素,可能从生活方式干预中获益,特别是那些针对抑郁、睡眠和体育活动的干预措施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79d5/11882794/15f314221c59/41598_2025_91178_Fig2_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验